about
Pleiotropic effects of type 2 diabetes management strategies on renal risk factors.Low-dose glucocorticoid treatment affects multiple aspects of intermediary metabolism in healthy humans: a randomised controlled trial.Cardiovascular, renal and gastrointestinal effects of incretin-based therapies: an acute and 12-week randomised, double-blind, placebo-controlled, mechanistic intervention trial in type 2 diabetes.Acute renal effects of the GLP-1 receptor agonist exenatide in overweight type 2 diabetes patients: a randomised, double-blind, placebo-controlled trialBiliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.The gut-renal axis: do incretin-based agents confer renoprotection in diabetes?Postprandial renal haemodynamic effect of lixisenatide vs once-daily insulin-glulisine in patients with type 2 diabetes on insulin-glargine: An 8-week, randomised, open-label trial.GLP-1 based therapies: clinical implications for gastroenterologists.SGLT2 Inhibition in the Diabetic Kidney-From Mechanisms to Clinical Outcome.Role of Insulin-Stimulated Adipose Tissue Perfusion in the Development of Whole-Body Insulin Resistance.Glomerular Hyperfiltration in Diabetes: Mechanisms, Clinical Significance, and Treatment.Exenatide acutely increases heart rate in parallel with augmented sympathetic nervous system activation in healthy overweight males.Heart rate acceleration with GLP-1 receptor agonists in type 2 diabetes patients: an acute and 12-week randomised, double-blind, placebo-controlled trial.The effects of GLP-1 based therapies on postprandial haemodynamics: Two randomised, placebo-controlled trials in overweight type 2 diabetes patients.Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial.Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial.Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.Uncomplicated human type 2 diabetes is associated with meal-induced blood pressure lowering and cardiac output increase.Acute plasma amylase increase after glucagon-like peptide -1 receptor agonist exenatide administration in Type 2 diabetes.Comment on Lovshin et al. Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes. Diabetes Care 2017;40:1073-1081.Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.Effect of immediate and prolonged GLP-1 receptor agonist administration on uric acid and its kidney clearance: post-hoc analyses of four clinical trials.Pancreatic Steatosis Is Not Associated With Exocrine Pancreatic Function in Overweight Type 2 Diabetes Patients.GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes.Does dipeptidyl peptidase-4 inhibition prevent the diabetogenic effects of glucocorticoids in men with the metabolic syndrome? A randomized controlled trial.SGLT2 inhibition: a new era in renoprotective medicine?SGLT2 Inhibitors in Combination Therapy: From Mechanisms to Clinical Considerations in Type 2 Diabetes ManagementLixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trialLixisenatide Versus Insulin Glulisine on Fasting and Postbreakfast Systemic Hemodynamics in Type 2 Diabetes Mellitus PatientsIncretin-based drugs and renoprotection—is hyperfiltration key?Combining incretin-based drugs and RAAS inhibitors: more cons than pros?Letter by Muskiet et al Regarding Article, "Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial"ACE-I vs. ARB for blood pressure control in diabetic kidney diseaseUnderstanding EMPA-REG OUTCOMERenoprotection in LEADER and EMPA-REG OUTCOMERenal outcomes in CVOTs: keep calm and carry onNew pharmacological strategies for protecting kidney function in type 2 diabetesGLP-1 receptor agonists, CKD, and eGFR trajectoryAssessment of real-time and quantitative changes in renal hemodynamics in healthy overweight males: Contrast-enhanced ultrasonography vs para-aminohippuric acid clearanceLiraglutide and Renal Outcomes in Type 2 Diabetes
P50
Q30374407-777CB29F-121B-4C68-A916-C4054DCA5163Q35091608-527976EB-31EF-41D6-8251-532FA2A1387EQ36302662-B29CE2B0-C66C-4F28-BF4C-2F54329EED06Q36990093-F44E5AD7-DA03-4742-914A-2FEC57015556Q37456235-813F4C70-FE47-4B27-9F0A-F34C9E871B18Q38174491-ADE8E395-86F6-4692-A222-DF6DC6A883E0Q38377453-32AAC614-26E2-4271-AD36-017732E15675Q38703292-FEFAAB52-A267-47A8-99F4-C248AC5ECAF8Q38932322-96A1F640-1043-4D7F-AF97-56F3E06A33B8Q39105620-244ADD3E-C656-4C99-A653-AE1453B7188AQ39112475-C6F55A13-EE4C-4D52-8178-8F10AABB939CQ39220482-D4E105BA-6CCA-416B-832C-3FF25704C543Q39253117-7E4FD5C6-1FB9-4D67-9039-48F4B11FC5CDQ40381711-853AB500-8C15-4819-BA3C-FE15B6C324E7Q40415039-3919B110-6EC3-4162-9F76-F77B4B7062A4Q40581820-1B6818B9-E8A5-4B7A-8497-29EE45678151Q40598164-44BC1A9D-F5E7-4175-85A7-3AD2719DF8CEQ41744813-529B1FB4-9633-4784-8B63-8824B53EC23DQ42314614-B6F5A194-3343-407E-B80E-7351C344E4AEQ48143847-ED97B50D-C758-48A0-976D-D5DF16722D5EQ48166975-08FDAF5A-59F9-43FA-ABD4-21B14C9BF308Q48227892-A03809E4-C001-48C3-8776-0106DB355BAFQ50118366-8472E06C-01F6-4DF6-931C-FA05084F9235Q50225916-7E215AA9-E9E7-4C49-9403-BD69A76598F6Q51330583-FEC17EBF-209E-4507-804E-C4F0C083B68BQ53185865-9EF66D22-CD79-43BA-BA6F-9D42EE047BE9Q57171956-E00F1050-FD02-4448-BC5A-C6D5E14099D5Q57190377-289CB810-FBDD-46B6-879B-EE0168CB61D1Q64355402-221F982D-C1AD-45CA-886A-129DB9D38096Q64355407-ABE59434-3801-4209-8789-99499856D9EEQ64355408-B77735F0-9943-40C3-9EA5-C3BAF64E9374Q85887888-76FE700A-60D5-43A1-8A4E-E4175EFBC3B0Q86062217-6FAC0AE9-D216-48E5-9ECA-59C807BCC484Q86756711-8A2C4D87-7838-41A1-8949-04753995DDB0Q88405448-3C9F11BC-8B5D-4BD4-AD82-C29F72CC5718Q89222809-FA4A44A6-2AA8-4A90-B16C-D368FB86FF59Q90719496-F49FCD22-726E-40D8-A00E-29222FC72782Q91854306-966F48FB-5BCF-4832-A9A4-D59D6FA87204Q91948819-7D432E56-9BAB-4F08-AA67-B8AEE485A310Q95764117-8DDCF094-235B-46AB-A3CE-0B8364466395
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Marcel H.A. Muskiet
@ast
Marcel H.A. Muskiet
@en
Marcel H.A. Muskiet
@es
Marcel Muskiet
@nl
type
label
Marcel H.A. Muskiet
@ast
Marcel H.A. Muskiet
@en
Marcel H.A. Muskiet
@es
Marcel Muskiet
@nl
altLabel
M. Muskiet
@nl
M.H.A. Muskiet
@nl
Marcel H.A. Muskiet
@nl
prefLabel
Marcel H.A. Muskiet
@ast
Marcel H.A. Muskiet
@en
Marcel H.A. Muskiet
@es
Marcel Muskiet
@nl
P108
P106
P31
P496
0000-0003-4116-555X